 | | Vol. 9.25 – 29 June, 2021 |
| |
|
|
| Researchers demonstrated that pharmacologic modulation of splicing via specific drug classes generated bona fide neoantigens and elicited anti-tumor immunity, augmenting checkpoint immunotherapy.
[Cell] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators examined the effect of B cell stimuli on lymphoid stromal cells in follicular lymphoma (FL). FL B cells interacted primarily with CD49a+ fibroblastic reticular cells.
[Immunity] |
|
|
|
| Scientists found that tumor-infiltrating follicular regulatory T cells were prevalent in tumor tissues of several cancer types.
[Nature Immunology] |
|
|
|
| By combining endoscopy-guided sampling of the biliary tree with a high-dimensional analysis approach, comprehensive mapping of the human biliary immunological landscape in patients with primary sclerosing cholangitis, a severe biliary inflammatory disease, was conducted.
[Science Translational Medicine] |
|
|
|
| Researchers complemented PD-L1 immunohistochemistry and tumor mutation burden with RNA-seq in 366 patients to identify unifying and indication-specific molecular profiles that could predict response to checkpoint blockade across tumor types.
[Nature Communications] |
|
|
|
| To learn whether inflammation alters cystic fibrosis (CF) airway surface liquid pH, researchers treated CF epithelia with TNFα and IL-17, two inflammatory cytokines that are elevated in CF airways.
[Journal of Clinical Investigation] |
|
|
|
| Using different preclinical models for liver metastasis, researchers found that tissue-resident type I innate lymphoid cells controlled metastatic seeding, whereas conventional NKs restrained outgrowth.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists investigated this topic in an in vitro model using primary human T cells and in an immuno-nutritional intervention study enrolling healthy volunteers.
[EMBO Molecular Medicine] |
|
|
|
| Researchers used multicolor flow cytometry and immunohistochemistry to elucidate abundance and spatial distribution of antigen-presenting B cells in blood and tumor samples of 238 cancer patients.
[Cancer Immunology Research] |
|
|
|
| Despite its well-documented inhibitory effects, higher PD-1 expression in tumor-infiltrating lymphocytes was significantly associated with longer survival in triple-negative breast cancer patients.
[Oncogene] |
|
|
|
| The authors explored the persistent upper airway inflammation and blood eosinophilia of s patient. Unlike wild-type T-bet, the mutant form of T-bet from this patient did not inhibit the production of Th2 cytokines, including IL-4, IL-5, IL-9, and IL-13, when overexpressed in T helper 2 (Th2) cells.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Investigators deeply investigated the impact of KIR, HLA class I, and CD16 genotypes on rituximab-dependent NK cell responses in both an in vitro cellular model from healthy blood donors and ex vivo rituximab-treated non-Hodgkin lymphoma patients.
[Oncoimmunology] |
|
|
|
| The authors analyzed the profiling of immune cells in the peripheral blood of steroid-sensitive nephrotic syndrome patients and steroid-resistant nephrotic syndrome patients before and after standard steroid treatment to clarify the immunological mechanism of nephrotic syndrome patients.
[Scientific Reports] |
|  |
|
|
|
| Researchers examined the recently discovered pathways involved in PD-L1 expression and highlight the relevant druggable strategies that are being developed to both improve the response rate and avoid the onset of resistance.
[Trends in Molecular Medicine] |
|
|
|
|
| In a move that will bring hope to liver transplant patients around the world, Lion TCR, a Singapore biotechnology company, has signed an exclusive worldwide licensing agreement with Duke-NUS Medical School to develop an innovative method of using gene-edited T cells to treat recurring cancers in the donated organ.
[Duke-NUS] |
|
|
|
| Takara Bio, Inc. announced that it has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies GmbH under which Takara Bio grants BioNTech a commercial license to use applicable patents relating to RetroNectin®.
[Takara Bio, Inc.] |
|
|
|
| Trillium Therapeutics, Inc. announced that it has dosed the first patient with TTI-621, an investigational checkpoint inhibitor of the innate immune system, in combination with doxorubicin in a Phase Ib/II study in leiomyosarcoma.
[Trillium Therapeutics, Inc.] |
|
|
|
|
| September 1 – 4, 2021
Virtual |
|
|
|
|
|
| | Heinrich Heine University Düsseldorf – Düsseldorf, Germany |
|
|
|
| | Weill Cornell Medical College – New York, New York, United States |
|
|
|
| | Research Center for Molecular Medicine – Vienna, Austria |
|
|
|
| | Hummingbird Bioscience – Singapore, Singapore |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
